0001437749-26-009387
SEC filingTalphera, Inc. (TLPH) reported a net loss of $14.3 million for FY 2025, widening from $13.0 million in FY 2024, driven by higher operating expenses amid ongoing development of lead product Niyad. Research and development expenses decreased 10% to $6.0 million from $6.7 million, reflecting reduced Niyad trial costs, while selling, general, and administrative expenses fell 12% to $7.5 million from $8.5 million due to lower consulting and board fees. No significant revenue was recognized, with only $28K in non-cash revenue from the sale of future payments. Balance sheet strengthened with total assets at $29.7 million, including $20.9 million in current assets (cash $5.9M, short-term investments $14.5M), and stockholders' equity of $17.0 million. Cash flows showed $11.4 million used in operations, $14.3 million used in investing (net investment purchases), offset by $22.7 million from financing via private placements. Net cash decreased $3.0 million to $5.9 million end balance. Liquidity of $20.4 million supports Niyad registrational trial completion expected 2026, but additional capital needed as going concern doubt persists.
Talphera reported FY 2025 net loss of $14.3M, compared to $13.0M in 2024, reflecting continued investment in Niyad development. R&D expenses declined to $6.0M (down 10% YoY from $6.7M) due to lower Niyad costs. SG&A fell to $7.5M (down 12% from $8.5M) from reduced consulting, board fees, and market research. Other expense of $0.9M included $1.3M warrant liability revaluation loss. Total assets $29.7M, liabilities $12.7M, equity $17.0M. Cash flows: operating use $11.4M, investing use $14.3M, financing provide $22.7M; net cash change -$3.0M.
No material revenue recognized. Non-cash revenue of -$28K related to sale of future DSUVIA payments. Company remains pre-commercial, focused on Niyad PMA submission post-2026 trial completion. Prior divestiture of DSUVIA classified as discontinued operations.
Pre-revenue stage precludes margins. Operating losses driven by R&D ($6.0M) and SG&A ($7.5M). No gross profit applicable. Warrant liability changes ($-1.3M loss) and prior non-cash interest ($0 in 2025 vs. $0.4M 2024) impact net results.
Operating cash use $11.4M, adjusted for $0.7M stock comp, -$1.3M warrant gain/loss, working capital shifts. Investing: -$14.3M net (purchases $17.8M, maturities $3.5M). Financing: $22.7M from equity raises. Balance sheet: current assets $20.9M (cash $5.9M, investments $14.5M), current liabilities $3.8M, warrant liability $2.4M, future payments liability $6.5M. Liquidity $20.4M.
Management focuses on Niyad registrational trial (NEPHRO CRRT, 70 patients, completion 2026) for PMA submission. Evaluating LTX-608 indications. Cash insufficient for 12+ months; plans additional financing via equity/debt. Going concern doubt noted; Nasdaq bid price compliance issue (180-day period to Sep 2026). Risks: trial delays, capital needs, supply chain (Asia CDMO).